A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.
Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…Blood derived α-synuclein seeding in the course of Parkinson’s Disease
Objective: To identify seeding capacities of soluble α-synuclein (α-syn) conformers derived from neuronal extracellular vesicles (NEs) from Parkinson´s disease (PD) patients with different disease durations…RT-QuIC for detection of pathological α-synuclein in the olfactory mucosa and CSF of Parkinson’s disease patients
Objective: To investigate the proficiency of RT-QuIC in detecting the presence of misfolded α-synuclein (α-syn) on the olfactory mucosa (OM) and CSF of patients with…Assessment of variation in α-synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia
Objective: To understand molecular heterogeneity among Parkinson’s disease (PD) patients, and controls based on α-synuclein seed amplification assay (SAA) results. Background: α-synuclein seed amplification assay…Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease
Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson’s disorder
Objective: Identification and evaluation of the potential of a novel NLR family pyrin domain containing 3 (NLRP3) inflammasome inhibitor (ZYIL1) as a Parkinson’s disease (PD)…Autosomal dominant Parkinson’s disease caused by SNCA p.E46K variant in family with Russian ancestry: A case report
Objective: To report a family with autosomal dominant Parkinson’s disease (PD) with SNCA p.E46K variant. Background: Alpha-synuclein, encoded by SNCA, is a part of Lewy…The effect of anti- Parkinson’s disease granules and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine -induced Parkinson’s disease
Objective: To investigate the effect of anti- Parkinson’s disease (anti-PD granules) and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine( MPTP )-induced PD. Background:…Selegiline drives autophagic secretion of α-synuclein
Objective: Our aim is to elucidate how selegiline drives extracellular secretion of α-synuclein (αS) and whether selegiline-induced αS secretion affects cell-to-cell transmission of αS. Background:…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 70
- Next Page »